Alx Oncology Holdings (ALXO) Interest Expenses (2019 - 2026)

Alx Oncology Holdings has reported Interest Expenses for 8 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Interest Expenses rose 844.83% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 123.02% YoY) and the FY2025 annual result came in at $149.7 million, up 2038.62% from the prior year.
• Interest Expenses grew to $3.8 million in Q1 2026 per ALXO's latest filing, from $383000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $3.8 million in Q1 2026 and troughed at $2000.0 in Q2 2022.
• A 5-year average of $668352.9 and a median of $406000.0 in 2025 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses tumbled 99.79% in 2022, then soared 19450.0% in 2023.
• Over 5 years, Interest Expenses stood at $231000.0 in 2022, then soared by 174.46% to $634000.0 in 2023, then sank by 30.76% to $439000.0 in 2024, then declined by 12.76% to $383000.0 in 2025, then jumped by 901.57% to $3.8 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $3.8 million, $383000.0, and $408000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.